Identifying Clinical and Genetic Characteristics of Spinal Muscular Atrophy Patients and Families in Saudi Arabia.

carriers case series kingdom of saudi arabia (ksa) mutation sma

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Oct 2023
Historique:
accepted: 30 09 2023
medline: 6 11 2023
pubmed: 6 11 2023
entrez: 6 11 2023
Statut: epublish

Résumé

 Spinal muscular atrophy (SMA) is an inherited, neuromuscular disease characterized by the deterioration of spinal motor neurons, causing progressive muscular atrophy and weakening. It is an autosomal recessive disease with the mutation of the survival motor neuron 1 (SMN1) gene as a hallmark. Evidence suggests that the SMN2 gene modulates the severity of the disease. SMA is classified based on the maximum motor function achieved. This study aims to describe the genetic makeup and characteristics of an SMA cohort in the Kingdom of Saudi Arabia (KSA).  Data from families presenting with SMA children was collected between January 2018 and December 2020. Blood samples were collected from patients and family members. Genetic testing for SMA and mutations was performed at a European central lab.  Seventeen families were enrolled in the study, including 52 children. Among 34 parents, 28 were carriers with heterozygous deletion (82.3%), one (2.9%) had no deletion detected by multiplex ligation-dependent probe amplification (MLPA) but had point mutation by sequencing, one (2.9%) had homozygous deletion and was symptomatic, three (8.8%) had no deletion or point mutation and were presumed to have 2+0, and one (2.9%) was not tested.  This study provides insight into the carrier mutational analysis of families with SMA disease manifestations in KSA. Further studies are needed to understand the burden and impact of SMA among the Saudi population.

Identifiants

pubmed: 37927698
doi: 10.7759/cureus.46452
pmc: PMC10623204
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e46452

Informations de copyright

Copyright © 2023, Alghamdi et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Eur J Hum Genet. 2005 Mar;13(3):309-13
pubmed: 15586177
Neurol Genet. 2020 Sep 01;6(5):e505
pubmed: 33062891
Pediatr Neurol. 2015 Oct;53(4):293-300
pubmed: 26260993
Am J Hum Genet. 2002 Feb;70(2):358-68
pubmed: 11791208
Int J Mol Sci. 2021 Jul 23;22(15):
pubmed: 34360669
Arq Neuropsiquiatr. 2018 Apr;76(4):265-272
pubmed: 29742241
Chin Med J (Engl). 2011 Feb;124(3):385-9
pubmed: 21362338
Neuromuscul Disord. 2018 Mar;28(3):208-215
pubmed: 29433793
Am J Hum Genet. 1999 May;64(5):1340-56
pubmed: 10205265
Orphanet J Rare Dis. 2011 Nov 02;6:71
pubmed: 22047105
Gene Ther. 2021 Nov;28(10-11):676-680
pubmed: 34276047
Am J Hum Genet. 1997 Nov;61(5):1102-11
pubmed: 9345102
Int J Mol Sci. 2020 May 07;21(9):
pubmed: 32392694
J Pediatr. 2017 Nov;190:124-129.e1
pubmed: 28711173

Auteurs

Alaa Alghamdi (A)

Primary Care and Population Health, King Fahad University Hospital, Dammam, SAU.

Shaikhah AlDossary (S)

Primary Care and Population Health, University College London, London, GBR.

Wala Abdulaziz Alabdulqader (W)

Physical Therapy, King Fahad Specialist Hospital, Dammam, SAU.

Fawzia Amer (F)

Pediatric Neurology, King Fahad Specialist Hospital, Dammam, SAU.
Pediatric Neurology and Metabolic, Cairo University Children Hospital, Cairo, EGY.

Mona Ali (M)

Neurology, Neuroscience Center, King Fahad Specialist Hospital, Dammam, SAU.

Momen Almomen (M)

Pediatric Neurology, King Fahad Specialist Hospital, Dammam, SAU.

Fouad Alghamdi (F)

Pediatric Neurology, Neuroscience Center, King Fahad Specialist Hospital, Dammam, SAU.

Classifications MeSH